Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
High Confidence RCTPrimary source: [Open]
Linked compounds: semaglutide
Outcomes summary
Large randomized trial evaluating cardiovascular outcomes in people with overweight/obesity and established cardiovascular disease without diabetes; semaglutide was associated with a reduction in major adverse cardiovascular events compared with placebo.
Limitations
Generalizability depends on enrolled population and background therapy; discontinuation and adherence influence estimands; results apply to the studied dose/indication context.
Notes
Primary source: PMID 37952131 (see PubMed link on this page).